Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis

NCT ID: NCT06215248

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

162 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEAD

LEAD diagnosis confirmed by by ankle-brachial index (≤0,9 or \>1,3) or angiography. Fontaine I-IV class symptoms.

No interventions assigned to this group

Controls

Matched with LEAD group's patients as much as possible for age, sex, smoking history, hypertension, diabetes, coronary artery disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fontaine I-IV class symptoms
* Confirmed diagnosis of LEAD


* Age 35-85
* Has to have at least of the following: hypertension, diabetes, coronary artery disease or the patient smokes

Exclusion Criteria

* Age \<35 or \>85 years
* BMI ≥40 kg/m²
* Known heart failure in history
* Any acute or chronic autoimmune or rheumatic disease
* Cardiac structural disease in history: inflammatory, infiltrative diseases, nonischemic cardiomyopathies
* Acute coronary syndrome in last 3 months
* Moderate to severe cardiac valvular disease
* Cardiac valvular disease operative/invasive treatment in history
* Cardiac implantable electronic device (CIED)
* Transitory ischemic attack or stroke in last 3 months
* Severe COPD (GOLD C or D)
* Moderate to severe asthma (according to GINA 2022 criteria)
* Untreated hypertension (noninvasive blood pressure measurement ≥180/110 mmHg during recruitment)
* Chronic severe kidney dysfunction (eGFR \<30 ml/min/1,73 m²)
* Malignant tumor with radiation treatment to thorax, oncologic or biologic treatment in history
* Chronic hematologic disease (except for anemia)
* Severe liver dysfunction
* Malignant tumor with \<5 years of remission
* Acute or chronic infectious disease
* Anemia with hemoglobin \<80 g/L
Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tartu University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jaak Kals

Professor of Vasology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jaak Kals, PhD

Role: PRINCIPAL_INVESTIGATOR

Tartu University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tartu University Hospital

Tartu, , Estonia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Estonia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jaak Kals, PhD

Role: CONTACT

731 8292 ext. +372

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Liis Roine, MD

Role: primary

+372 731 8457

Related Links

Access external resources that provide additional context or updates about the study.

https://endothelialcentre.ut.ee/

Endothelial Research Centre

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

23105

Identifier Type: -

Identifier Source: org_study_id